Cerecor Inc (NASDAQ:CERC) insider James Archie Harrell, Jr. acquired 3,064 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average price of $4.18 per share, for a total transaction of $12,807.52.
NASDAQ CERC opened at $4.41 on Friday. The stock’s 50-day simple moving average is $3.48 and its two-hundred day simple moving average is $3.91. Cerecor Inc has a twelve month low of $2.71 and a twelve month high of $7.65. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.71 and a current ratio of 0.73.
Cerecor (NASDAQ:CERC) last released its quarterly earnings results on Thursday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. Cerecor had a negative return on equity of 121.32% and a negative net margin of 113.66%. The business had revenue of $5.61 million for the quarter, compared to the consensus estimate of $5.15 million. Research analysts predict that Cerecor Inc will post -0.4 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. purchased a new stake in Cerecor during the second quarter valued at about $288,000. Northern Trust Corp raised its position in Cerecor by 47.4% during the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock valued at $304,000 after purchasing an additional 17,999 shares in the last quarter. Bank of New York Mellon Corp raised its position in Cerecor by 294.9% during the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after purchasing an additional 42,885 shares in the last quarter. JPMorgan Chase & Co. raised its position in Cerecor by 612.7% during the second quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after purchasing an additional 62,473 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Cerecor during the third quarter valued at about $305,000. Institutional investors and hedge funds own 60.84% of the company’s stock.
A number of equities research analysts recently issued reports on CERC shares. ValuEngine downgraded Cerecor from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Maxim Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Cerecor in a research report on Friday, November 15th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $10.00 price objective on shares of Cerecor in a research report on Friday, December 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Cerecor in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $10.67.
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Recommended Story: What is a price target?
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.